Artivion, Inc. (NYSE:AORT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $44.8333.

A number of analysts have issued reports on the stock. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Citigroup restated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Stifel Nicolaus set a $45.00 target price on Artivion in a report on Monday, June 1st. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Artivion in a research report on Monday, July 20th. Finally, Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th.

Insiders Place Their Bets

In other news, CEO James Mackin sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew Green sold 11,480 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 90,460 shares of company stock valued at $2,557,366 in the last quarter. 6.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its holdings in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Artivion in the 2nd quarter valued at about $103,000. Pictet Asset Management Holding SA grew its position in Artivion by 25.6% in the first quarter. Pictet Asset Management Holding SA now owns 5,520 shares of the company’s stock worth $202,000 after acquiring an additional 1,125 shares in the last quarter. Finally, Commerce Bank purchased a new position in Artivion in the second quarter worth about $208,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Stock Down 2.6%

NYSE AORT opened at $23.50 on Friday. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.15 billion, a PE ratio of -335.65 and a beta of 1.25. The stock’s 50 day moving average is $26.30 and its 200 day moving average is $27.97.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Research analysts predict that Artivion will post 0.45 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.